Thymulin

1. Overview

Thymulin, originally designated Facteur Thymique Serique (FTS, "Serum Thymic Factor"), is a zinc-dependent nonapeptide exclusively produced by thymic epithelial cells [1][4]. It was discovered in 1977 by Jean-Francois Bach and Mireille Dardenne at the Institut Necker in Paris through a bioassay measuring the induction of T-cell differentiation markers (rosette formation) in mouse thymocytes [1][5]. Thymulin holds the distinction of being the only known thymic hormone that requires a metal cofactor -- equimolar zinc (Zn2+) -- for its biological activity [2].

The complete sequence of thymulin is pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, where pGlu represents pyroglutamic acid (cyclized N-terminal glutamate) [1]. The zinc-free peptide (FTS or apo-thymulin) is biologically inactive, while the zinc-bound form (Zn-FTS or metallic thymulin) possesses full immunomodulatory activity [2]. This zinc dependency creates a direct biochemical link between zinc nutritional status and thymic endocrine function, with profound implications for immunosenescence and immune health across the lifespan [3][7][10].

Thymulin is exclusively produced by subcapsular and medullary thymic epithelial cells, and its presence in serum serves as a specific marker of thymic endocrine function [4][17]. Serum thymulin levels peak during childhood (ages 2-10 years), begin declining after puberty, and become very low or undetectable after age 60, closely paralleling the age-related involution of the thymus gland [6][9]. This progressive decline has made thymulin a central biomarker in the study of immunosenescence -- the age-related deterioration of the immune system.

Molecular Weight

~857 Da (nonapeptide); ~921 Da (zinc-bound form)

Sequence

pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn

Metal Cofactor

Zinc (Zn2+) -- required for biological activity

Half-life

Very short (minutes); rapidly inactivated in serum

Source

Exclusively thymic epithelial cells

FDA Status

Not approved. Research compound.

Discovery

Jean-Francois Bach, 1977 (Institut Necker, Paris)

2. Mechanism of Action

Zinc-Dependent Activation

The zinc dependency of thymulin was established by Dardenne et al. in 1982, who demonstrated that equimolar Zn2+ binding is required for the peptide's ability to induce T-cell differentiation [2]. Zinc coordinates with the peptide through the side chains of Lys3 and Ser4 and the backbone carbonyl of Ala2, creating a conformational change that exposes the biologically active epitope. Chelation of zinc by EDTA or DTPA completely abolishes thymulin activity, which can be restored by adding exogenous zinc [2][7].

This zinc requirement explains the well-documented immune deficiency associated with zinc-deficient states. Prasad et al. (1988) showed that mild zinc deficiency in elderly subjects resulted in reduced plasma thymulin activity, which was restored by zinc supplementation [3]. The relationship is bidirectional: zinc deficiency reduces thymulin bioactivity, and age-related thymulin decline can be partially reversed by zinc supplementation [3][18][19].

T-Cell Differentiation

Thymulin promotes the maturation of T-lymphocyte precursors within the thymus and in the peripheral circulation [1][5]. Specific effects include induction of CD2 and CD3 expression on immature thymocytes, promotion of the double-negative to double-positive T-cell transition, modulation of CD4/CD8 T-cell subset ratios, and enhancement of alloantigen recognition and mixed lymphocyte reaction responses [1][9][17].

Cytokine Modulation

Thymulin modulates the production of both pro-inflammatory and anti-inflammatory cytokines. In inflammatory contexts, thymulin suppresses excessive production of TNF-alpha, IL-1beta, and IL-6 while maintaining or enhancing IL-10 and IL-2 production [12][13]. This balanced immunomodulatory profile distinguishes thymulin from purely immunosuppressive agents.

NK Cell Enhancement

Thymulin enhances natural killer cell cytotoxic activity, an effect that is dependent on adequate zinc availability. Mocchegiani et al. (1995) demonstrated that zinc supplementation in elderly subjects restored both thymulin levels and NK cell function, suggesting that the age-related decline in NK cytotoxicity is partially mediated through thymulin deficiency [18].

Anti-Inflammatory and Analgesic Properties

Recent research has revealed that thymulin possesses direct anti-inflammatory and analgesic properties independent of its classical immunomodulatory role. Safieh-Garabedian et al. (2000) demonstrated that intracerebroventricular thymulin (10-100 ng) produced potent analgesia in inflammatory pain models, mediated through reduction of central nervous system IL-1beta, IL-6, and TNF-alpha [11]. Lunin et al. (2013) showed that thymulin attenuated LPS-induced neuroinflammation, reducing brain cytokine levels, microglial activation, and sickness behavior [13].

3. Researched Applications

3.1 Immunosenescence and Aging

The progressive decline of thymulin with age represents one of the most well-documented endocrine changes associated with immunosenescence [6][9]. Dardenne et al. (1983) established the age-related thymulin curve in a cross-sectional study of healthy subjects aged 2-80 years [6]. This decline correlates with reduced T-cell output, impaired T-cell function, increased susceptibility to infections, diminished vaccine responses, and increased cancer incidence in the elderly [7][8][20].

Zinc supplementation has been shown to partially reverse this decline. Mocchegiani et al. (1995) demonstrated that 15 mg zinc daily for 6 months increased plasma thymulin activity, improved peripheral T-cell function, and enhanced NK cell cytotoxicity in elderly subjects [18]. Similar results were obtained in Down syndrome patients, who exhibit accelerated thymic involution and premature immunosenescence [20].

3.2 Zinc Deficiency and Immune Function

The thymulin-zinc axis provides a mechanistic explanation for the well-known immune deficiency associated with zinc-deficient states [3][10]. Prasad et al. (1988) demonstrated that even mild zinc deficiency (common in the elderly, alcoholics, and malnourished individuals) reduces circulating thymulin activity, contributing to impaired T-cell immunity [3]. Zinc supplementation restores thymulin-dependent immune parameters including T-cell proliferative responses, IL-2 production, and delayed-type hypersensitivity [10][20].

3.3 Neuroinflammation and Neuroprotection

A growing body of evidence supports thymulin's role as a neuromodulatory peptide. Lunin et al. (2010, 2013) demonstrated that thymulin administration reduced neuroinflammation in models of systemic LPS challenge, attenuating microglial activation, reducing brain pro-inflammatory cytokine levels, and decreasing oxidative stress markers [12][13].

Reggiani et al. (2017) showed that intranasal zinc-thymulin promoted remyelination, reduced astrogliosis, and improved motor coordination in the cuprizone-induced demyelination model, which is relevant to multiple sclerosis [16]. This work extended earlier findings by Reggiani et al. (2012, 2014) showing neuroprotective effects of thymulin gene therapy in the central nervous system [14][15].

3.4 Thymulin Gene Therapy

Reggiani et al. (2014) developed an innovative approach using adeno-associated viral vectors encoding a synthetic thymulin gene (metFTS) for neonatal gene therapy. This approach prevented the age-associated decline in thymic and immune function in treated animals, maintaining thymulin levels and immune parameters into old age [14]. The gene therapy approach circumvents thymulin's extremely short half-life, providing sustained production of the peptide.

4. Clinical Evidence Summary

5. Dosing in Published Research

6. Safety and Side Effects

Direct clinical safety data for thymulin administration are limited because most human studies have used indirect restoration of thymulin activity through zinc supplementation rather than direct peptide administration.

Zinc supplementation at 15 mg/day for 6 months was well tolerated in elderly subjects with no significant adverse effects [18][20]. Higher doses of zinc (greater than 40 mg/day) can cause gastrointestinal disturbance and copper deficiency with prolonged use.

In preclinical studies, thymulin and zinc-thymulin complex have demonstrated good tolerability with no reported organ toxicity at experimental doses [11][13][16]. The peptide's short half-life and endogenous origin suggest a favorable safety profile, though systematic clinical safety evaluation has not been conducted.

7. Pharmacokinetics

Thymulin's pharmacokinetics are uniquely governed by its zinc-dependent bioactivity, creating a two-tier system in which the peptide's physical presence and biological activity follow different kinetic profiles [2][3][6].

Endogenous Production and Circulating Levels: Thymulin is exclusively synthesized and secreted by thymic epithelial cells, making it the only thymic hormone with a confirmed single-organ source [1][4][17]. In healthy young individuals, circulating thymulin levels are detectable in the low nanomolar range using the rosette bioassay. Serum levels peak during childhood (ages 2-10 years), plateau through adolescence, begin declining after age 20-25, and become very low or undetectable by age 60 [6][9]. This decline curve closely mirrors the histological involution of the thymus gland.

Plasma Half-Life: Exogenous thymulin (both zinc-bound and zinc-free forms) has a very short circulating half-life in the range of minutes, reflecting rapid enzymatic degradation by serum peptidases [6][12]. The nonapeptide size (9 amino acids, approximately 857 Da apo-form) provides no protection against proteolysis, and the pyroglutamic acid N-terminus, while offering some aminopeptidase resistance, does not substantially extend survival. This ultrashort half-life has been a major obstacle to direct therapeutic administration and has driven the development of alternative delivery strategies (gene therapy, intranasal formulations) [14][16].

Zinc-Dependent Bioactivity: The biologically active species is exclusively the zinc-bound form (Zn-FTS, approximately 921 Da). The zinc-free peptide (apo-FTS) circulates in plasma but is immunologically inert [2]. The equilibrium between active Zn-FTS and inactive apo-FTS is directly determined by local and systemic zinc availability. In zinc-replete individuals, the majority of circulating thymulin is in the active zinc-bound form; in zinc-deficient states, the proportion of active thymulin drops even before total thymulin peptide levels decline [2][3][7].

Zinc Supplementation Kinetics: Mocchegiani et al. (1995) showed that oral zinc supplementation (15 mg/day) in elderly subjects increased measurable thymulin bioactivity within 1-3 months, with maximal restoration at 6 months [18]. This restoration occurs by converting pre-existing circulating apo-thymulin to active Zn-thymulin, not by stimulating new peptide synthesis from the involuted thymus. The kinetic implication is that zinc supplementation can restore thymulin function even when thymic production capacity is severely reduced [3][18][19].

Intranasal Delivery: Reggiani et al. (2017) demonstrated that intranasal zinc-thymulin complex bypasses the blood-brain barrier, achieving CNS exposure relevant for neuroprotective applications [16]. This route avoids systemic degradation and provides direct access to brain tissue, representing a pharmacokinetically favorable strategy for CNS applications.

Gene Therapy Approach: Reggiani et al. (2014) developed adeno-associated viral vectors encoding synthetic thymulin (metFTS) for sustained endogenous production, circumventing the half-life limitation entirely [14]. This approach maintained thymulin levels into old age in treated animals, demonstrating proof-of-concept for overcoming pharmacokinetic barriers through gene therapy.

8. Dose-Response Relationships

T-Cell Differentiation (In Vitro): In the original rosette bioassay, thymulin induces T-cell differentiation markers on immature thymocytes at concentrations in the picomolar to low nanomolar range, making it among the most potent thymic peptides on a molar basis [1][5]. Half-maximal activity in the rosette assay occurs at approximately 1-10 nM for the zinc-bound form. The zinc-free peptide shows no activity even at micromolar concentrations, confirming the absolute zinc requirement [2].

Anti-Inflammatory Effects (Preclinical): Safieh-Garabedian et al. (2000) demonstrated dose-dependent analgesia with intracerebroventricular thymulin in rat inflammatory pain models. Doses of 10 ng, 50 ng, and 100 ng produced progressively greater analgesic effects, with 100 ng producing near-maximal reduction of inflammatory hyperalgesia [11]. The anti-inflammatory mechanism (reduction of CNS IL-1beta, IL-6, TNF-alpha) followed a parallel dose-response curve.

Anti-Neuroinflammatory Effects: Lunin et al. (2013) showed that thymulin reduced LPS-induced brain cytokine levels in a dose-dependent manner, with significant reductions in TNF-alpha, IL-1beta, and microglial activation markers at doses that paralleled the analgesic dose-response curve [13].

Zinc Supplementation Dose-Response: The thymulin-restoring effect of zinc supplementation follows a dose-dependent curve with a ceiling effect. Mocchegiani et al. (1995) found that 15 mg zinc daily for 6 months produced substantial thymulin restoration and immune parameter improvement [18]. Higher zinc doses (30-45 mg/day) may not provide additional thymulin activation benefit and carry risks of copper depletion and gastrointestinal side effects. The optimal dose appears to be in the 15-25 mg/day range for elderly subjects with mild zinc insufficiency [10][20].

Remyelination Dose-Response: Reggiani et al. (2017) showed that intranasal zinc-thymulin promoted remyelination in the cuprizone model in a manner dependent on treatment duration, with daily administration for 2-4 weeks required for measurable histological and functional improvement [16].

9. Comparative Effectiveness

Thymulin vs. Thymosin Alpha-1

Thymosin alpha-1 (Ta1, 28 amino acids) and thymulin (9 amino acids) are derived from entirely different precursors and act through distinct mechanisms. Ta1 activates toll-like receptors (TLR2/9) and dendritic cells, functioning primarily as an innate immune enhancer, while thymulin acts on T-cell precursors to drive maturation and modulates cytokine balance [1][17]. Ta1 has a markedly longer half-life (approximately 2 hours) compared to thymulin (minutes), enabling practical subcutaneous dosing. Ta1 has achieved regulatory approval in over 35 countries (as Zadaxin) with Phase III clinical data in hepatitis B and cancer immunotherapy, while thymulin remains a research compound without regulatory approval for direct administration. However, thymulin has unique advantages: it is the only thymic peptide with demonstrated neuroprotective and analgesic properties, and its zinc dependency provides a nutritional intervention pathway (zinc supplementation) that indirectly restores thymulin function without requiring peptide administration [3][11][13][18]. For immunosenescence, zinc-mediated thymulin restoration is practical, inexpensive, and well-tolerated, whereas Ta1 requires ongoing peptide injections.

Thymulin vs. Thymopentin

Thymulin and thymopentin (TP-5, 5 amino acids) both promote T-cell differentiation but through different receptor systems. Thymopentin replicates the activity of thymopoietin (residues 32-36), while thymulin is a distinct gene product with zinc dependency [1][2]. Thymopentin has been approved in Italy and China with clinical trial data in HIV, rheumatoid arthritis, and primary immunodeficiency -- a more developed clinical profile than thymulin. However, thymopentin's half-life (approximately 30 seconds) is even shorter than thymulin's, and it lacks thymulin's zinc-dependent regulatory mechanism, neuroprotective properties, and gene therapy development potential [5][14][16]. Thymulin's unique zinc axis enables indirect therapeutic manipulation through nutritional intervention, a strategy unavailable for thymopentin.

Thymulin's Unique Position

Among thymic peptides, thymulin occupies a distinctive niche as the only metallopeptide hormone, the only thymic hormone with confirmed exclusive thymic origin (making it a specific biomarker of thymic function), the only thymic peptide with demonstrated CNS neuroprotective properties, and the only one amenable to indirect restoration through a nutritional intervention (zinc supplementation) [2][3][13][16].

10. Enhanced Safety Profile

Zinc Supplementation Safety

Since the primary clinical application of thymulin biology involves zinc supplementation rather than direct peptide administration, the safety profile is largely defined by zinc pharmacology [18][20].

Recommended Zinc Doses (15-25 mg/day): Well tolerated in elderly populations across multiple studies. Mocchegiani et al. (1995, 2006) reported no significant adverse effects with 15 mg zinc daily for 6 months in elderly subjects [18][20]. Improved immune parameters and reduced infection rates were observed without toxicity.

Higher Zinc Doses (greater than 40 mg/day): Associated with dose-dependent gastrointestinal symptoms (nausea, abdominal cramps, diarrhea) and, with prolonged use, copper deficiency leading to microcytic anemia and neutropenia [10]. The tolerable upper intake level for adults is 40 mg/day of elemental zinc.

Direct Thymulin Administration Safety

Preclinical data from intracerebroventricular, intraperitoneal, and intranasal thymulin administration studies show good tolerability with no reported organ toxicity [11][13][16]. The peptide's endogenous nature and short half-life minimize systemic accumulation risk. Safieh-Garabedian et al. (2000) reported no adverse behavioral or neurological effects at the highest tested ICV dose (100 ng) [11]. Intranasal zinc-thymulin in the cuprizone model (Reggiani et al., 2017) showed no nasal mucosal toxicity, systemic zinc overload, or behavioral abnormalities with daily dosing for 2-4 weeks [16].

Theoretical Considerations

Autoimmune Risk: As with all T-cell-stimulating agents, there is a theoretical concern about exacerbating autoimmune conditions. However, thymulin's balanced immunomodulatory profile -- suppressing pro-inflammatory cytokines (TNF-alpha, IL-1beta) while maintaining IL-10 -- suggests immunoregulatory rather than purely immunostimulatory activity, which may reduce this risk [12][13].

Zinc Homeostasis: Excessive zinc supplementation can disrupt copper and iron metabolism. Thymulin-targeted zinc supplementation should use the minimum effective dose (15-25 mg/day) with monitoring of copper status in prolonged regimens [10][20].

Systemic Safety of Gene Therapy: The thymulin gene therapy approach (AAV-metFTS) raises standard gene therapy safety considerations including vector immunogenicity, insertional mutagenesis risk, and long-term transgene expression control. These are generic gene therapy considerations rather than thymulin-specific toxicities [14].

11. The Zinc-Thymulin-Aging Axis

The relationship between zinc, thymulin, and immune aging represents one of the most compelling examples of nutritional regulation of endocrine immune function [7][8][20]:

1. Young adulthood: Thymic epithelial cells produce abundant thymulin; adequate zinc status ensures full bioactivity; robust T-cell output and immune function
2. Middle age (30-50 years): Thymic involution begins; thymulin production declines; may be partially compensated by adequate zinc nutrition
3. Advanced age (60+ years): Severe thymic involution; thymulin production minimal; zinc deficiency common; compounded immunodeficiency
4. Zinc supplementation: Can partially restore thymulin bioactivity even when thymic production is reduced, by converting inactive apo-thymulin to active Zn-thymulin [3][18]

This axis has implications for understanding why zinc supplementation improves immune function in the elderly and why zinc-deficient populations (elderly, malnourished, chronically ill) are disproportionately susceptible to infections.

12. Historical Context

• 1974: Dardenne and Bach identify the epithelial origin of a serum thymic factor [4]
• 1977: Bach et al. publish the biochemical characterization of FTS (thymulin) in Nature [1]
• 1977: FTS sequence determined: pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn
• 1982: Dardenne et al. discover the essential zinc dependency of thymulin [2]
• 1983: Age-related decline of serum thymulin documented across the human lifespan [6]
• 1988: Prasad et al. demonstrate zinc supplementation restores thymulin in deficient elderly [3]
• 1993: Dardenne and Bach publish comprehensive review of thymulin biology [17]
• 1995: Mocchegiani et al. show zinc reversal of immunosenescence-associated thymulin decline [18]
• 2000: Discovery of thymulin analgesic and anti-inflammatory properties in the CNS [11]
• 2013: Lunin et al. demonstrate anti-neuroinflammatory effects [13]
• 2014: Reggiani et al. develop thymulin gene therapy approach [14]
• 2017: Intranasal zinc-thymulin shown to promote remyelination in demyelination model [16]

13. Related Peptides

See also: Thymosin Alpha-1, Thymalin, Thymopentin, Epithalon

14. References

1. [1] Bach JF, Dardenne M, Pleau JM, Rosa J (1977). Biochemical characterisation of a serum thymic factor. Nature. PubMed
2. [2] Dardenne M, Pleau JM, Nabarra B, et al. (1982). Contribution of zinc and other metals to the biological activity of the serum thymic factor. Proceedings of the National Academy of Sciences. PubMed
3. [3] Prasad AS, Meftah S, Abdallah J, et al. (1988). Serum thymulin in human zinc deficiency. Journal of Clinical Investigation. PubMed
4. [4] Dardenne M, Papiernik M, Bach JF, Stutman O (1974). Studies on thymus products. III. Epithelial origin of the serum thymic factor. European Journal of Immunology. PubMed
5. [5] Dardenne M, Bach JF (1975). The sheep cell rosette assay for the evaluation of thymic hormones. Annals of the New York Academy of Sciences. PubMed
6. [6] Dardenne M, Pléau JM, Baronne R, et al. (1983). Thymulin (FTS) and zinc. International Journal of Immunopharmacology. PubMed
7. [7] Mocchegiani E, Giacconi R, Muzzioli M, Cipriano C (2000). Zinc, infections and immunosenescence. Mechanisms of Ageing and Development. PubMed
8. [8] Mocchegiani E, Muzzioli M, Giacconi R (2000). Zinc, metallothioneins, immune responses, survival and ageing. Biogerontology. PubMed
9. [9] Mocchegiani E, Santarelli L, Tibaldi A, et al. (1998). Presence of links between zinc and melatonin during the circadian cycle in old mice: effects on thymic endocrine activity and on the survival. Journal of Neuroimmunology. PubMed
10. [10] Prasad AS (2008). Zinc in human health: effect of zinc on immune cells. Molecular Medicine. PubMed
11. [11] Safieh-Garabedian B, Poole S, Allchorne A, et al. (2000). Contribution of interleukin-1beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. British Journal of Pharmacology. PubMed
12. [12] Lunin SM, Novoselova EG (2010). Thymulin as a prospective anti-inflammatory agent. Expert Opinion on Biological Therapy. PubMed
13. [13] Lunin SM, Novoselova EG, Novoselova TV, et al. (2013). Thymulin controls inflammatory response and attenuates oxidative stress. Peptides. PubMed
14. [14] Reggiani PC, Herenu CB, Morel GR, et al. (2014). Neonatal thymulin gene therapy prevents the age-associated decline in thymic and immune function. Gene Therapy. PubMed
15. [15] Reggiani PC, Barbeito CG, Zuccolilli GO, et al. (2012). Neuroprotective effect of thymulin in the central nervous system. Annals of the New York Academy of Sciences. PubMed
16. [16] Reggiani PC, et al. (2017). Intranasal zinc-thymulin promotes remyelination in cuprizone model. Neurobiology of Disease. PubMed
17. [17] Dardenne M, Savino W (1994). Control of thymus physiology by peptidic hormones and neuropeptides. Immunology Today. PubMed
18. [18] Mocchegiani E, Fabris N (1995). Age-related thymus involution: zinc reverses in vitro the thymulin secretion defect. International Journal of Immunopharmacology. PubMed
19. [19] Mocchegiani E, et al. (1995). Reversibility of thymic involution and of age-related peripheral immune dysfunctions by zinc supplementation in old mice. International Journal of Immunopharmacology. PubMed
20. [20] Mocchegiani E, Romeo J, Malavolta M, et al. (2013). Zinc: dietary intake and impact of supplementation on immune function in elderly. Age. PubMed